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Abstract 
Guidelines recommend oral anticoagulant (OAC) monotherapy without antiplatelet 
therapy in patients with non-valvular atrial fibrillation (AF) with stable coronary artery 
disease (CAD) of >1 year after myocardial infarction or percutaneous coronary intervention. 
More evidences are required for the safety and efficacy of OAC monotherapy compared to 
OAC plus antiplatelet therapy. PubMed, EMBASE, and Cochrane Database of Systematic 
Reviews were systematically searched up to February 2019. Nonrandomized studies and 
randomized clinical trials comparing OAC monotherapy with OAC plus single antiplatelet 
therapy (SAPT) for patients with stable CAD and non-valvular AF. The primary endpoint was 
major adverse cardiovascular events (MACEs, composite of ischemic or thrombotic events) 
and secondary outcomes included major bleeding, stroke, all-cause death, and net adverse 
events (NAEs, composite of ischemic, thrombotic, or bleeding events). From 6 trials, 8,855 
patients were included. There was no significant difference in MACE in AF patients treated 
using OAC plus SAPT compared to those treated with OAC monotherapy (hazard ratio [HR], 
1.09; 95% confidence interval [CI], 0.92-1.29). OAC plus SAPT was associated with a 
significantly higher risk of major bleeding compared to OAC monotherapy (HR, 1.61; 95% 
CI, 1.38-1.87), as well as in terms of NAE (HR, 1.21; 95% CI, 1.02-1.43). There were no 
significant differences in rates of stroke and all-cause death. In conclusion, in this meta-
analysis, OAC monotherapy and OAC plus SAPT treatment showed similar effectiveness, but 
OAC monotherapy was significantly associated with a lower risk of bleeding compared to 
OAC plus SAPT in patients with non-valvular AF and stable CAD. 
 
Keywords: atrial fibrillation, stable coronary artery disease, oral anticoagulation, meta-
analysis 
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Introduction 
Coronary artery disease (CAD) is accompanied in one third of atrial fibrillation (AF) 
patients.
1
 The oral anticoagulant (OAC) and antiplatelet therapy (APT) are essential treatment 
for AF patients with CAD who have undergone percutaneous coronary intervention (PCI).
2,3
 
Particularly in AF patients with stable CAD for >1 year after the acute coronary events or 
PCI, either OAC monotherapy or combined OAC with single antiplatelet therapy (SAPT) is 
recommended according to their risk of future coronary events.
4-6
 Although several 
observational and prospective registries have evaluated the optimal treatment for patients 
with stable CAD and AF,
7-10
 there are limited data from randomized controlled trials (RCTs) 
regarding the use of OAC monotherapy. The result of OAC-ALONE trial remains 
inconclusive due to being under-powered.
11
 We thus conducted a systematic review and 
performed a meta-analysis to compare the efficacy and safety of OAC monotherapy and OAC 
plus single antiplatelet therapy (SAPT) in AF patients with stable CAD. 
 
Methods 
We performed electronic searches of PubMed, EMBASE and the Cochrane Database 
of Systematic Reviews to identify studies that included specific keywords relevant to this 
topic. We added manual search results, including references cited in electronically searched 
articles, recent reviews, editorials, and meta-analyses. We did not apply any restrictions 
regarding the language, study period, or sample size. A description of the detailed study 
methods including search strategy are included in the Supplement. 
The inclusion criteria for studies in this meta-analysis were as follows: 1) the study 
should be published before February 2019; 2) clinical endpoints should be clearly reported; 3) 
the study should include stable CAD (defined as 1 year after any MI or PCI) patients with AF; 
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4) a comparison of outcomes between OAC monotherapy and OAC plus SAPT should be 
presented. Two investigators (S-R Lee and T-M Rhee) independently screened titles and 
abstracts from the search results, removed duplicates, investigated full articles and 
determined if they should be included in the analysis. The primary endpoint was a major 
adverse cardiovascular event (MACE, a composite of ischemic or thrombotic events) and 
secondary outcomes included major bleeding, stroke or systemic thromboembolism, all-cause 
death, and net adverse events (NAEs, a composite of ischemic, thrombotic, or bleeding 
events). 
We acquired the data for analysis and the description of study characteristics using a 
standardized extraction form. We assessed the quality of eligible studies using the Cochrane 
Collaboration’s tool for assessing the risk of bias, the Newcastle-Ottawa Scale (NOS) and the 
strengthening the reporting of observational studies in epidemiology (STROBE) checklist. 
We applied random-effect models to analyze primary and secondary endpoints and 
pooled hazard ratios (HR) are presented with 95% confidence intervals (CI) as statistical 
summaries. Heterogeneity between studies was quantified using I
2
 statistics. Publication bias 
was assessed qualitatively using funnel plot asymmetry and quantitatively using Egger’s and 
Begg’s tests. 
Subgroup analyses were used to assess differential effects between various subgroups. 
Two-sided p-values <0.05 were considered to statistically significant. We followed the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (eTable 1 
in the Supplement) and the Meta-analysis of Observational Studies in Epidemiology 
(MOOSE) guidelines. 
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Results 
Figure 1 presents an overview of the search and selection process used in this meta-
analysis. A total of 8,855 patients with stable CAD and non-valvular AF were included in the 
6 studies. A summary of important study characteristics can be found in Table 1 and eTable 4 
in the Supplement. Only recent publications included DOAC users (27%, 40.6%, and 24.8% 
of total study population).
9-11
 Patients with DOAC accounted for 8.6% of total of 8,855 
pooled patients, irrespective of whether they were prescribed OAC monotherapy or OAC 
plus SAPT. Both aspirin and clopidogrel were included as SAPT therapies. The definitions of 
major bleeding in included studies were largely consistent with the International Society on 
Thrombosis and Hemostasis (ISTH) major bleeding criteria. 
Risk of bias of each study was assessed using the Cochrane Collaboration’s tool for 
RCT, and the Newcastle-Ottawa Scale for non-randomized studies (eTable 2 and 3 in the 
Supplement). The bias risk of both RCT and non-randomized studies was low, providing high 
methodologic quality of this meta-analysis. 
In our main analysis, we observed no significant heterogeneity for the all endpoints. 
In this population of patients with stable CAD and non-valvular AF, OAC plus SAPT was 
associated with an increased risk of major bleeding (pooled HR, 1.61; 95 % CI, 1.38-1.87) 
while there was no significant difference in MACE when compared to OAC monotherapy 
(pooled HR, 1.09; 95 % CI, 0.92-1.29) (Figure 2). Funnel plots, along with the Egger’s and 
the Begg’s test, showed no significant publication bias for MACE. Although some asymmetry 
was observed for major bleeding, the result remained consistent after trim-and-fill method 
(eFigure 1 in the Supplement). 
There was no significant difference in rates of all-cause death (pooled HR, 1.07; 95 % 
CI, 0.91-1.27) and stroke (pooled HR, 0.99; 95% CI, 0.70-1.40). Compared to OAC 
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monotherapy, OAC plus SAPT showed a significantly worse outcomes in NAE (pooled HR, 
1.21; 95 % CI, 1.02-1.43) (Figure 3). 
In general, consistent findings were observed in various subgroup analyses (Figure 4). 
The subgroup analyses did not reveal any significant heterogeneity in various subgroups. 
OAC plus SAPT tended to show higher risk of MACE than OAC monotherapy in the 
subgroup that >60% of total population had previous history of MI (HR, 1.35; 95% CI, 0.96-
1.88). Results were consistent in the subgroup by the stent type mainly used in the studies 
(BMS or DES). OAC plus SAPT tended to show higher risk of bleeding than OAC 
monotherapy regardless of the subgroup by VKA only versus VKA/DOAC. 
 
Discussion 
Our principal findings are as follows: (1) the pooled HR for major bleeding and NAE 
were significantly higher in the OAC plus SAPT group, while there were no significant 
differences in MACE, stroke, and death; (2) in general, consistent findings were observed in 
various subgroup analyses, including BMS and DES studies; (3) OAC monotherapy showed 
more benefit for MACE in the subgroup with higher proportion of previous MI patients; (4) 
in the studies after the introduction of DOACs, OAC monotherapy was generally safer and 
had comparable MACE to that of OAC plus SAPT. This meta-analysis is the first to include 
data from the OAC-ALONE study, which is the first RCT evaluating safety and efficacy of 
OAC monotherapy and OAC plus SAPT.
11
 
A substantial proportion of patients with AF have concomitant CAD and are at risk of 
acute coronary events requiring PCI at some point in their lives.
1,12
 Irrespective of APT 
regimens used, omission of OAC is regarded as inadequate for stroke prevention in patients 
with AF; however, the comorbidities of CAD and concomitant use of APT lead to 
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underutilization of OAC, often due to concerns about the risk of bleeding.
13-16
 A recent report 
that primary prevention through aspirin is harmful in terms of bleeding without any benefit 
evokes a need to review the current medical practice of using APT routinely.
17
 Also, many 
physicians have misconception that APT is more mandatorily considered in AF patients with 
CAD; therefore, OAC is largely underused in these patients or alternatively, such patients 
receive unnecessary treatment, which can substantially increase the risk of bleeding.
18
 
Although guidelines generally recommend OAC monotherapy for AF patients with 
stable CAD, the evidence that stands for the use of OAC monotherapy has been limited.
5,6,19
 
A Danish nationwide registry study demonstrated that when compared to other 
antithrombotic regimen, VKA plus SAPT was not more beneficial for prevention of 
thromboembolism; however, it significantly increased the risk of bleeding compared to VKA 
monotherapy.
18
 Subsequent prospective studies reported that VKA alone resulted in no 
difference in MACE, but led to a decreased risk of bleeding compared with VKA plus 
SAPT.
7,8
 
 In the PREFER-in-AF and PREFER-in-AF PROLONGATION registries, OAC 
monotherapy significantly reduced both ACS and major bleeding, leading to a clear net 
clinical benefit.
10
 The benefits of OAC monotherapy in ACS indicate that the OAC plus 
SAPT group may be at an increased risk of both thromboembolic and bleeding events, which 
is consistent with the result of the subgroup analysis in this meta-analysis. Notably, in the 
OAC plus SAPT group, the use of antithrombotic agents is likely to be interrupted by the 
bleeding events, which may increase the incidence of MACE in high risk patients. 
Furthermore, since most evidence to date is from non-randomized studies, unmeasured 
confounders such as physician's discretion cannot be ignored. It is possible that the 
assignment to either OAC monotherapy or OAC plus SAPT group was affected by the 
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individual bleeding risk. 
Following these cohort studies, the first RCT comparing OAC versus OAC plus 
SAPT in AF patients with stable CAD was performed,
11
 but the patient enrollment was 
prematurely terminated due to slow enrollment and the number of study patients was smaller 
than originally planned. The significance of non-inferiority of OAC monotherapy compared 
to OAC plus SAPT was not achieved for the primary composite outcome (all-cause death + 
MI + stroke/systemic embolism), while was established for the secondary composite outcome 
(primary composite outcome + major bleeding) (HR: 0.99; 95% CI: 0.71-1.39; p = 0.016 for 
non-inferiority). Although the study was under-powered and inconclusive, the findings were 
consistent with previous cohort studies, demonstrating that OAC plus SAPT had no 
significant benefit when compared to OAC monotherapy. 
In our meta-analysis, OAC plus SAPT treatment was significantly associated with an 
increased risk of major bleeding as well as NAE, without a significant reduction in cardiac 
and cerebral ischemic events compared to OAC monotherapy. Our findings are largely 
consistent with previous studies. 
Prescription of DOACs for stroke prevention has been rapidly increasing in patients 
with non-valvular AF, since their introduction, as an effective, safe, and convenient 
alternative to VKA.
1,14,20
 In this study, a large portion of OAC treatment was performed using 
VKA, and only recent studies have included patients treated with DOAC or DOAC plus 
SAPT.
9-11
 In the subgroup analysis, the results were consistent for both VKA and 
VKA/DOAC studies. At the time of the systematic search for the present meta-analysis, we 
found no clinical trials directly comparing the use of DOAC monotherapy with DOAC plus 
SAPT in AF patients with stable CAD. Although 2 randomized clinical trials are undergoing 
with DOACs (NCT 02642419 and NCT 03718559),
21
 more evidence are required given the 
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recent report that worse efficacy may be seen in DOAC compared to VKA.
22
 Real-world 
cohort studies are also warranted to analyze the various factors that affect the practical use of 
DOAC, such as the dosing regimen, adherence or compliance issue, and the fluctuation of 
renal function. 
This study has several limitations. First, the treatment quality of VKA, represented as 
time in therapeutic range, was not thoroughly evaluated in all studies included in this analysis. 
Second, some studies in this meta-analysis reported the mean CHA2DS2-VASc score (4.7-4.9
8
, 
4.7
9
, and 4.6
11
) and HAS-BLED score (3.1
9
) of the total study population, but the reporting 
methods for CHA2DS2-VASc and HAS-BLED scores varied between the studies. Therefore, 
we could not explore whether significant interactions exist among subgroups stratified by 
these scores. Third, we could not analyze whether there was a particular clinical subgroup in 
which OAC plus SAPT treatment may be beneficial. The procedural characteristics were not 
available for most of the studies included, thus limiting the scope of this analysis. Lastly, 
since many of included studies were performed in the VKA era,
7,8,18
 further studies are 
required, particularly those including DOACs as the OAC therapy used. In addition, 
subsequent studies should include comparisons with new antiplatelet drugs that have not been 
adequately addressed in previous studies. 
In conclusion, OAC monotherapy and OAC plus SAPT treatment showed similar 
effectiveness, but OAC monotherapy was significantly associated with a lower risk of 
bleeding compared to OAC plus SAPT in patients with non-valvular AF and stable CAD. 
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Figure legends 
Figure 1. Study flow 
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Figure 2. Pooled hazard ratio of MACE and major bleeding comparing OAC 
monotherapy versus OAC plus SAPT 
(A) Major adverse cardiovascular events 
(B) Major bleeding 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
16 
 
Abbreviation: MACE, major adverse cardiovascular events; OAC, oral anticoagulant; SAPT, 
single antiplatelet therapy. 
 
 
 
Figure 3. Pooled hazard ratio of all-cause death, stroke, and net adverse events 
comparing OAC monotherapy versus OAC plus SAPT 
 (A) All-cause death 
 (B) Stroke 
 (C) Net adverse events 
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Abbreviation: OAC, oral anticoagulant; SAPT, single antiplatelet therapy. 
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Figure 4. Subgroup analyses for MACE and major bleeding 
Abbreviation: MACE, major adverse cardiovascular events. 
 
 
 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
19 
 
 
Table 1. Characteristics of Studies Selected for Analysis 
   
Number of 
patients 
  Demographics of overall population 
First author of 
study 
Study 
period 
Study design 
OAC 
alone 
OAC 
+ APT 
Type of 
OAC 
Type of APT 
Mean 
age 
(Years) 
Male MI 
Type 
of 
stent 
Lamberts 
(2014) (Aspirin) 
2002-
2011 
Observational 
registry 
950 1471 VKA Aspirin 73.4 66.1% 78.8% NR 
Lamberts 
(2014) 
(Clopidogrel) 
2002-
2011 
Observational 
registry 
950 322 VKA Clopidogrel 73.0 64.2% 74.3% NR 
Hamon (2014) 
2010-
2011 
Prospective 
cohort 
119 342 VKA 
Aspirin or 
clopidogrel 
NR NR NR NR 
Lemesle (2017) 
2003-
2004 
Prospective 
cohort 
1481 866 VKA 
Aspirin or 
clopidogrel 
73.2 71.2% 54.8% NR 
Fischer (2018) 
2010-
2015 
Observational 
registry 
172 434 
VKA or 
DOAC 
Aspirin or 
clopidogrel 
76.0 68.9% 45.3% 
BMS 
or 
DES 
Patti (2018) 
2012-
2016 
Observational 
registry 
710 348 
VKA or 
DOAC 
Aspirin or 
clopidogrel 
74.1 78.6% 68.3% 
BMS 
or 
DES 
Matsumura-
Nakano (2018) 
2013-
2016 
Randomized 
trial 
344 346 
VKA or 
DOAC 
Aspirin or 
clopidogrel 
75.1 85.2% 38.6% 
BMS 
or 
DES 
Abbreviations: APT, antiplatelet therapy; BMS, bare-metal stent; DES, drug-eluting stent; DOAC, direct oral 
anticoagulant; MI, myocardial infarction; NR, not reported; OAC, oral anticoagulant; VKA, vitamin K 
antagonist. 
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Highlights 
 
 Evidence for optimal antithrombotic regimen for AF with stable CAD is limited. 
 
 This meta-analysis compared outcomes between OAC monotherapy and OAC plus 
SAPT. 
 
 OAC monotherapy showed similar efficacy but significantly lower risk of bleeding. 
 
 Further evidence regarding DOAC in AF patients with stable CAD is required. 
 
